Document is current
Any future updates will be listed below
-
Authors
Tyan, Kevin https://orcid.org/0000-0002-8585-1802
Baginska, Joanna
Brainard, Martha
Giobbie-Hurder, Anita
Severgnini, Mariano
Manos, Michael
Haq, Rizwan
Buchbinder, Elizabeth I.
Ott, Patrick A.
Hodi, F. Stephen
Rahma, Osama E.
-
Funding
Funding for this research was provided by:
Parker Institute for Cancer Immunotherapy (5812101)
- License Information
-
More Information
Article History
Received: 15 September 2020
Accepted: 6 January 2021
First Online: 22 January 2021
Compliance with ethical standards
:
: The authors report the following competing interests: RH has research grant support from Novartis and BMS as well as a consulting arrangement with Tango Therapeutics. EB has served on advisory boards for Array Biopharma, Bristol-Myers Squibb (BMS), Trieza Therapeutics and Novartis, and she also receives clinical trial support from Eli Lilly, Novartis, BMS, Genentech and BVD. PO reports the following: advisory roles for Alexion, Array, BMS, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, and TRM Oncology; institutional grants from Armo Biosciences, AstraZeneca/MedImmune, BMS, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, and Pfizer; and a speaking engagement from Medscape. SH reports the following: grants from BMS and Novartis; personal fees from BMS, Merck, Serono, Novartis, Takeda, Surface Pharmaceuticals, Genentech/Roche, Compass Therapeutics, Apricity, Bayer, Aduro, Partners Therapeutics, Sanofi, Pfizer, Pionyr Immunotherapeutics, 7 Hills Pharma, Verastem Oncology, Rheos Medicines, and Kairos Therapeutics; equity in Torque Therapeutics; and patents #20100111973 and #7250291 issued as well as #20170248603, #20160340407, #20160046716, #20140004112, #20170022275, #20170008962, and “Methods of Using Pembrolizumab and Trebananib” pending. OER has research support from Merck. Speaker for activities supported by educational grants from BMS and Merck. Consultant for Merck, Celgene, Five Prime, GSK, Bayer, Roche/Genentech, Puretech, Imvax, and Sobi. In addition, OER has patent “Methods of using pembrolizumab and trebananib” pending.
: Patients evaluated in this study were identified from the Dana-Farber Cancer Institute melanoma bio-specimen banking protocol (DFCI IRB approved protocol 05-042).
: Patients evaluated in this study were identified from the Dana-Farber Cancer Institute melanoma bio-specimen banking protocol (DFCI IRB approved protocol 05-042).
